Study of Orally-Administered AMXT 1501 Dicaprate in Normal Healthy Volunteers
Stopped Change in FDA required patient population decision prior to study start, new protocol developed, this protocol withdrawn
Conditions
- Neoplasms
- Medication Toxicity
- Tolerance
Interventions
- DRUG: AMXT 1501
- DRUG: Placebo Oral Tablet
Sponsor
Aminex Therapeutics, Inc.
Collaborators
- [object Object]
- [object Object]